Chemotherapy News and Research

Latest Chemotherapy News and Research

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Combination of new prostate cancer drugs can extend life for men

Combing two new prostate cancer drugs could increase the number of men who respond to treatment and the length of time they benefit, research led by The Institute of Cancer Research (ICR) has shown.

2 May 2012

NKCC1 protein may hold clues to how glioblastoma moves and invades

Johns Hopkins researchers have discovered that a protein that transports sodium, potassium and chloride may hold clues to how glioblastoma, the most common and deadliest type of brain cancer, moves and invades nearby healthy brain tissue.

2 May 2012

Idera to present data from IMO-8400 preclinical studies on SLE, psoriasis at AAI meeting

Idera Pharmaceuticals, Inc. today announced that it will be presenting data from preclinical studies of its Toll-like receptor (TLR) inhibitor, IMO-8400, in models of systemic lupus erythematosus (SLE) and psoriasis, which suggest that IMO-8400 may be useful for the treatment of both indications.

2 May 2012

Ciprofloxacin, TMP-SMX no longer safe for outpatient urinary tract infection

In a surveillance study of over 12 million bacteria, investigators at The George Washington University and Providence Hospital found E. coli antimicrobial resistance to ciprofloxacin, the most commonly prescribed antimicrobial for urinary tract infections in the U.S., increased over five-fold from 2000 to 2010.

2 May 2012

Chemo-radiotherapy combination a viable alternative for frail bladder cancer patients

Bladder cancer patients given low doses of chemotherapy combined with radiotherapy were nearly 50 per cent less likely to relapse with the most lethal form of the disease compared to those given radiotherapy alone, a major trial funded by Cancer Research UK shows.

2 May 2012

Trovagene completes PCR assay development for detection of K-RAS mutations

Trovagene, Inc., a developer of trans-renal molecular diagnostics, announced today that the Company has successfully completed the analytical development of digital PCR assays for the detection of the most prevalent K-RAS mutations, which are, according to recent estimates, observed in more than 90% of pancreatic cancers, and in 23% of all solid tumors.

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

BTG launches Voraxaze for treatment of toxic plasma methotrexate

BTG International Inc., the specialist healthcare company today announces the launch of Voraxaze (glucarpidase) in the US. Voraxaze is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.

30 Apr 2012

MCC researchers aim to improve cancer patient's quality of life and care

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

30 Apr 2012

WCI sponsors 5th Annual Jean Sindab Triple Negative Breast Cancer Symposium

The 5th Annual Jean Sindab Triple Negative Breast Cancer Symposium, sponsored by the Winship Cancer Institute at Emory University, provides an intimate learning environment in which the most current advances in triple-negative breast cancers (TNBC) will be explored.

30 Apr 2012

Aspirin can reduce chance of dying from bowel cancer by 30%

Taking aspirin after being diagnosed with bowel cancer can reduce the chance of dying from the disease by 30 per cent, new research shows today.

27 Apr 2012

Mammography remains beneficial for women in their 40s

Researchers from University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine have published new findings that mammography remains beneficial for women in their 40s.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Aspirin reduces bowel cancer death and lung cancer incidence: Research suggests

There is previous evidence suggesting aspirin might prevent certain cancers from developing in the first place. And more recent work suggests it might also work as a cancer therapy - slowing down or preventing a cancer's spread. But the drug can also have unpleasant and dangerous side effects, causing irritation of the stomach lining and internal bleeds in a very small minority of patients.

26 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

IMPAKT 2012 breast cancer conference to focus on four major areas

"Basic science and clinical medicine move at different pace because they follow different paths. Both however aim at improving strategies to manage cancer patients. We need to efficiently translate the good things from basic science and efficiently implement them in the clinic."

26 Apr 2012

RANK inhibitor-chemotherapy combination may have important therapeutic effects against breast cancer

Researchers from the Bellvitge Biomedical Research Institute (IDIBELL) have shown that overactivation of the RANK signalling pathway promotes the initiation, progression and metastasis of tumours in human breast epithelial cells by dedifferentiation of breast cells to stem cells. The results of this study have been advanced in the electronic edition of the journal Cancer Research.

25 Apr 2012

Sheffield researchers investigate ways to improve treatment for elderly patients with breast cancer

Sheffield researchers are investigating ways to improve the treatment and survival rate of elderly patients diagnosed with breast cancer.

25 Apr 2012

MMP-10 gene plays a dual role in lung cancer

A single gene that promotes initial development of the most common form of lung cancer and its lethal metastases has been identified by researchers at Mayo Clinic in Florida.

25 Apr 2012